# Contraception in adolescents with mental disorders: adherence and satisfaction in the use of depot medroxyprogesterone acetate

## TL;DR

This study examines how well adolescents with mental disorders stick to and are satisfied with a specific contraceptive method.

## Contribution

The study provides insights into contraceptive adherence and satisfaction among adolescents with mental disorders, a less-researched population.

## Key findings

- About half of the adolescents continued using DMPA after 12 months.
- The most common reasons for discontinuation were irregular bleeding and weight gain.
- Satisfaction with DMPA was reported by over half of the participants.

## Abstract

To evaluate the continuation rate, satisfaction, and reasons for discontinuation of depot medroxyprogesterone acetate (DMPA) in adolescents treated in a mental health service.

Prospective cohort study conducted in a reference unit for the care of adolescents with mental disorders (MDs) and intellectual disabilities (IDs). All patients received a gynecological consultation and an educational group on contraceptive methods. Sociodemographic data on age, education and gynecological data (menarche, coitarche, regularity of menstrual cycles and presence of symptoms) were collected. Follow-up was quarterly for 12 months, during which symptoms, desire to continue, and satisfaction with the use of the quarterly injectable were assessed.

Eight hundred and sixty-two sexually active adolescents were supported, 532 adolescents chose to use the quarterly injectable, and 69 of these agreed to participate in the study. The mean age of users was 15.5 years (SD=0.91). After 12 months of follow-up, 34 (49.3%) of the 69 adolescents continued to use the method and 36 (52.3%) were satisfied. Among the 33 (47.8%) who discontinued use, the most common reasons were irregular bleeding and weight gain.

Adolescents with intellectual disabilities and/or other mental disorders showed a significant rate of continuation and satisfaction with the use of the depot medroxyprogesterone acetate at 12 months, and the most common reasons for discontinuation were irregular uterine bleeding and weight gain.